{
  "id": "everyday#risk_safety_0119f18d",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "1. Introduction 1.1 Background and rationale based guidelines were developed in accordance with the WHO handbook for guideline development Mental, neurological and substance use (MNS) (10). The 2015 version included 23 new and updated disorders are prevalent in all regions of the world and recommendations and nine priority conditions: are major contributors to morbidity and premature depression; psychosis; bipolar disorders; epilepsy; mortality. In 2019, they caused 10.1% of all global developmental and behavioural disorders in children burden of disease as measured in disability-adjusted and adolescents; dementia; alcohol use disorders; life-years (DALYs) and 25.1% of all years lived with drug use disorders; and self-harm/suicide and other disability (1). The resources that have been provided significant emotional or medically unexplained to tackle the huge burden of MNS disorders are complaints (7). The priority conditions were selected as insufficient, inequitably distributed and inefficiently they represented a large burden in terms of mortality, used (2). The result is a large treatment gap, more morbidity or disability; have high economic costs; than 75% in many countries with low and lower and are often associated with violations of human middle incomes (1,3). The stigma and discrimination rights. Additionally, as part of the scaling-up strategy associated with MNS conditions further exacerbates of mhGAP in countries, derivative products based on the issues and creates additional barriers for people to mhGAP guidelines were developed. seek and access care (4). In keeping with WHO’s practice of regularly monitoring To reduce the treatment gap and to enhance the new and emerging evidence, a new edition of the capacity of countries to respond to the growing mhGAP guideline is now timely. The first and second challenge, the World Health Organization (WHO) editions of the mhGAP guideline, and derivative developed the Mental Health Gap Action Programme products, have been used by more than 100 countries (mhGAP) (5). mhGAP has provided health planners, and translated into more than 20 languages over the policy-makers and donors with a set of clear and past 11 years. There has been a rapid expansion in the coherent activities and programmes for scaling up care use of the guideline since 2015. A systematic review for MNS disorders. An essential component of mhGAP found that 33 studies reported use of mhGAP in 2017 is the evidence-based guideline for MNS disorders (11). This review was recently updated, with authors identified as conditions of high priority for low- and noting a substantial increase in use of mhGAP with 162 middle-income countries (LMICs). new studies published since 2018 (12). mhGAP was launched in 2008 (5) and the first set The widespread use of mhGAP has important of WHO recommendations was published in 2010 implications, from direct clinical care to policy and as part of the mhGAP intervention guide (2,6).",
  "gloss_vi": "1. introduction 1.1 background and rationale based guidelines were developed in accordance with the who handbook for guideline development mental, neurological and substance use (mns) (10).",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety"
    ],
    "life_topics": [],
    "advice_section": [],
    "audience": [],
    "risk_band": "high"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn 1. Introduction 1.1 Background and rationale based guidelines were developed in accordance with the WHO handbook for guideline development Mental, neurological and substance use (MNS) (10). The 2015 version included 23 new and updated disorders are prevalent in all regions of the world and recommendations and nine priority conditions: are major contributors to morbidity and premature depression; psychosis; bipolar disorders; epilepsy; mortality. In 2019, they caused 10.1% of all global developmental and behavioural disorders in children burden of disease as measured in disability-adjusted and adolescents; dementia; alcohol use disorders; life-years (DALYs) and 25.1% of all years lived with drug use disorders; and self-harm/suicide and other disability (1). The resources that have been provided significant emotional or medically unexplained to tackle the huge burden of MNS disorders are complaints (7). The priority conditions were selected as insufficient, inequitably distributed and inefficiently they represented a large burden in terms of mortality, used (2). The result is a large treatment gap, more morbidity or disability; have high economic costs; than 75% in many countries with low and lower and are often associated with violations of human middle incomes (1,3). The stigma and discrimination rights. Additionally, as part of the scaling-up strategy associated with MNS conditions further exacerbates of mhGAP in countries, derivative products based on the issues and creates additional barriers for people to mhGAP guidelines were developed. seek and access care (4). In keeping with WHO’s practice of regularly monitoring To reduce the treatment gap and to enhance the new and emerging evidence, a new edition of the capacity of countries to respond to the growing mhGAP guideline is now timely. The first and second challenge, the World Health Organization (WHO) editions of the mhGAP guideline, and derivative developed the Mental Health Gap Action Programme products, have been used by more than 100 countries (mhGAP) (5). mhGAP has provided health planners, and translated into more than 20 languages over the policy-makers and donors with a set of clear and past 11 years. There has been a rapid expansion in the coherent activities and programmes for scaling up care use of the guideline since 2015. A systematic review for MNS disorders. An essential component of mhGAP found that 33 studies reported use of mhGAP in 2017 is the evidence-based guideline for MNS disorders (11). This review was recently updated, with authors identified as conditions of high priority for low- and noting a substantial increase in use of mhGAP with 162 middle-income countries (LMICs). new studies published since 2018 (12). mhGAP was launched in 2008 (5) and the first set The widespread use of mhGAP has important of WHO recommendations was published in 2010 implications, from direct clinical care to policy and as part of the mhGAP intervention guide (2,6). 1. introduction 1.1 background and rationale based guidelines were developed in accordance with the who handbook for guideline development mental, neurological and substance use (mns) (10)."
}